Psychedelic

A psychedelic is a psychoactive substance that produces marked changes in perception, cognition, and emotion through partial agonism at the serotonin 5-HT_2A receptor.^[1] Membership in the class is pharmacological rather than structural: substances from three chemically unrelated families converge on the same receptor target, and that convergence — not any shared chemical backbone — is what unites them.

Most psychedelics converge on partial agonism at the serotonin 5-HT_2A receptor in cortical layer V pyramidal neurons and in thalamocortical projection neurons.^[1] Activation disinhibits pyramidal output, raises cortical glutamate release, and disrupts the thalamic gating that normally filters sensory and associative content before it reaches awareness.^[2]

The mechanistic detail — which chemical family delivers the 5-HT_2A signal — matters less than the shared endpoint. Pre-treatment with the selective 5-HT_2A antagonist ketanserin abolishes the subjective effects of psilocybin, LSD, and DMT in human studies, confirming the receptor as the necessary initiating event across the class.^[1] Downstream, Gq protein recruitment — rather than β-arrestin-2 signalling — best predicts which 5-HT_2A agonists produce psychedelic effects, explaining why some receptor binders (e.g. lisuride) are non-hallucinogenic.

Several members carry additional pharmacology that shapes phenomenology without changing the defining target. The NBOMe series adds high-affinity adrenergic activity that drives a distinctive cardiovascular toxicity profile.^[4] The beta-carbolines harmine and harmaline are reversible MAO-A inhibitors rather than direct 5-HT_2A agonists; they belong to the class through their role in ayahuasca, where peripheral MAO-A inhibition makes oral DMT bioavailable.

These members differ widely in potency, duration, and route, but each engages the same 5-HT_2A mechanism that defines the class.

The psychedelic experience tracks a single axis — deepening 5-HT_2A-mediated disruption of cortical and thalamic information processing — as exposure rises.^[2]

A defining feature distinguishes the class from the deliriants: insight is generally preserved. Even at high exposures individuals typically remain aware that the experience is drug-induced. The same neural axis that produces the sought perceptual and affective shifts also produces transient anxiety, paranoia, and panic when set, setting, or dose push the experience past what the individual can integrate. Autonomic accompaniment — mild tachycardia, modest blood pressure elevation, pupil dilation — is consistent but clinically modest in healthy individuals.^[1]

Hallucinogen Persisting Perception Disorder (HPPD) — visual snow, geometric patterns, and motion trails that continue beyond the acute drug period — is a real but uncommon adverse outcome; one survey reported a medically-diagnosed lifetime rate of 1.3% among users versus 0.3% in non-users.^[5] A personal or family history of psychotic or bipolar disorder is an established contraindication.

Interaction themes are well documented across the class.^[6] Tryptamine psychedelics combined with MAOIs raise the risk of serotonin syndrome — the ayahuasca preparation is itself an MAOI–tryptamine combination, so any additional serotonergic medication (SSRIs, SNRIs, or prescribed MAOIs) compounds that risk.

Chronic SSRI use more often attenuates psychedelic effects than amplifies them, through 5-HT_2A downregulation, though frank serotonin toxicity remains possible. LSD combined with lithium has been associated with seizures in case reports and is regarded as clinically significant. Antipsychotics block psychedelic effects via 5-HT_2A antagonism and are used clinically to abort or attenuate a difficult experience.

Tolerance & dependence

Tolerance develops with striking speed across the class.^[7] A single full-dose exposure produces a measurably blunted response 24 hours later, and repeated daily dosing produces near-complete tolerance within a few days through downregulation of 5-HT_2A receptors in frontal cortex. Cross-tolerance is essentially complete across tryptamines, phenethylamines, and ergolines because all members converge on the same receptor population. Receptor sensitivity typically returns toward baseline within roughly one to two weeks of abstinence.

Physical dependence is not a feature of the class. Classical psychedelics are not self-administered in standard animal models, do not produce a clinically significant withdrawal syndrome on cessation, and carry low addiction liability relative to other scheduled substances.^[1][3] Psychological dependence is possible but uncommon; the rapid tolerance itself acts as a natural brake on escalating use.

The psychedelic class sits within the broader Hallucinogen category, which also includes the deliriants, the dissociatives, and other agents that produce perceptual alterations through unrelated mechanisms. Among its hallucinogen siblings, the deliriants form the sharpest contrast: they share the broad label "hallucinogen" but diverge in mechanism, phenomenology, and safety logic.

The insight-preserving versus insight-losing distinction is the most clinically useful axis at the bedside. A patient who knows they have taken a drug and remains oriented to the situation is presenting with a psychedelic profile; a patient who is disoriented and cannot separate hallucination from environment is presenting with a deliriant — or anticholinergic — profile, which calls for a very different emergency response.